In this randomized trial, children with bulky stage I/II disease with anemia had significantly better event-free survival after randomization to RT despite rapid and complete radiologic response to chemotherapy. Despite recent enthusiasm for Purpose: To evaluate whether clinical risk factors could further distinguish children with intermediate-risk Hodgkin lymphoma (HL) with rapid early and complete anatomic response (RER/CR) who benefit significantly from involved-field RT (IFRT) from those who do not, and thereby aid refinement of treatment selection. Methods and Materials: Children with intermediate-risk HL treated on the Children's Oncology Group AHOD 0031 trial who achieved RER/CR with 4 cycles of chemotherapy, and who were randomized to 21-Gy IFRT or no additional therapy (nZ716) were the subject of this study. Recursive partitioning analysis was used to identify factors associated with clinically and statistically significant improvement in event-free survival (EFS) after randomization to IFRT. Bootstrap sampling was used to evaluate the robustness of the findings. Result: Although most RER/CR patients did not benefit significantly from IFRT, those with a combination of anemia and bulky limited-stage disease (nZ190) had significantly better 4-year EFS with the addition of IFRT (89.3% vs 77.9% without IFRT; PZ.019); this benefit was consistently reproduced in bootstrap analyses and after adjusting for other prognostic factors. Conclusion: Although most patients achieving RER/CR had favorable outcomes with 4 cycles of chemotherapy alone, those children with initial bulky stage I/II disease and anemia had significantly better EFS with the addition of IFRT as part of combinedmodality therapy. Further work evaluating the interaction of clinical and biologic factors and imaging response is needed to further optimize and refine treatment selection.
Introduction
For children with Hodgkin lymphoma (HL), the combination of chemotherapy and involved-field radiation therapy (IFRT) produces excellent cure rates, with event-free survival (EFS) exceeding 85% in most recently published trials (1) (2) (3) . However, because of therapy-related late toxicity (4-6), selection of treatment intensity remains a clinical challenge, especially with respect to optimally refining the use of radiation therapy (RT). It would be ideal to find a group of patients for whom RT can be omitted without a significant increase in the rate of relapse, and conversely, to provide RT only to patients for whom there is a clinically significant benefit. Utilization of RT based on end of chemotherapy anatomic response alone can significantly increase the risk of relapse (7) , and consequently recent clinical trials have evaluated early chemotherapy response assessment as a means of identifying patients with highly chemo-sensitive disease for whom RT can be omitted without a clinically significant loss of disease control. The Children's Oncology Group (COG) AHOD 0031 trial evaluated a response-based treatment approach (2) . Among intermediate-risk patients with both rapid early anatomic response and complete response (RER/CR; determined by CT imaging), IFRT did not produce a significant improvement in 4-year EFS compared with adriamycin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) chemotherapy alone (87.9% vs 84.3%, PZ.11) (2).
However, this trial enrolled a clinically heterogeneous group of patients (ie, IA with bulk-IVA) with a broader range of risk factors than most adult "intermediate risk" trials. Consequently, there is some uncertainty regarding whether 4 cycles of chemotherapy alone was adequate for all RER/CR patients and whether treatment could be more optimally refined according to individuals' clinical characteristics.
The present analysis was undertaken to evaluate whether clinical risk factors could further distinguish intermediaterisk RER/CR patients who seemed to benefit significantly from IFRT from those who did not, and thereby aid refinement of treatment selection.
Methods and Materials Patients
From September 2002 to October 2009, 1712 eligible patients were enrolled. Patients under the age of 22 years with a newly diagnosed, pathologically confirmed intermediate-risk HL were eligible. Intermediate-risk was defined as any of the following clinical stages: IA to IIA with bulk, IAE to IIAE, IB to IIB, IIIA, or IVA. Large mediastinal adenopathy (LMA) was defined as tumor diameter more than a third of the thoracic diameter at the level of the diaphragm on an upright posterioreanterior chest radiograph. Extramediastinal lymph node aggregate measuring >6 cm in transverse diameter on axial CT was also considered as peripheral bulk disease.
Treatment protocol and response criteria
Initial chemotherapy for all patients consisted of 2 cycles of ABVE-PC (2) . Early response to therapy was then assessed on CT imaging. Patients with a 60% or more reduction in the product of perpendicular diameters (PPD) of all nodal abnormalities were considered RER and continued with 2 additional cycles of ABVE-PC, whereas patients not meeting this criterion were classified as slow early responders. At completion of the 4th cycle, complete response (CR) to chemotherapy was defined as a !80% reduction of all of the PPD. Fluorodeoxyglucose positron emission tomography (FDG-PET) imaging was reviewed by a single reader and graded such that uptake greater than mediastinal blood pool was categorized as positive. Imaging with PET was, however, not mandatory in this trial. Patients with both an RER and CR who were randomized to IFRT or no additional treatment are the subjects of the present analysis. Involvedfield RT (21 Gy) was given to all initial areas involved by HL with or without immediately adjacent uninvolved nodes.
Statistical analysis
Seven hundred sixteen patients achieved an RER/CR with chemotherapy and were randomized to IFRT or observation. Event-free survival was the primary endpoint in the study. The Kaplan-Meier method was used to estimate 4-year EFS according to the presence/absence of the following clinical variables: age, gender, stage (I/II, III, IV), B symptoms, any bulk disease, bulky mediastinal mass, extralymphatic disease, number of disease sites ( 2, 3-4, !5), histology (nodular sclerosis, other), erythrocyte sedimentation rate (<50 mm/h vs !50 mm/h), serum albumin (<3.5 g/dL vs !3.5 g/dL), and anemia (hemoglobin level of <11.5 g/dL for children younger than 12 years, and for older patients, <12 g/dL for females and <13 g/dL for males). A log-rank test was performed to compare the distribution of 4-year EFS between groups.
Grouping of continuous and ordinal variables was done before examining the results.
To identify factors that predict for superior EFS with combined modality therapy, recursive partitioning analysis (RPA) was used to identify patients with the greatest increase in the hazard ratio (HR) of EFS with the omission of IFRT among the predefined levels of the clinical variables listed above (8) . The variable with the largest increase in EFS without IFRT was then combined with all levels of the remaining variables to identify the variable combinations with the largest increase in HR without RT, provided there were at least 10 events in both the IFRT and no-IFRT groups (9) .
From this process we identified patient subgroups with combinations of characteristics that predicted clinically significant improvements in 4-year EFS (predefined as >7%) after randomization to IFRT. To evaluate the robustness of the HR and EFS estimates for these models, 1000 bootstrap samples were taken from each of the subgroups meeting these criteria, with replacement. In each case, the subgroup was chosen first, and then the bootstrap resamples were taken on the subgroup to evaluate a 95% confidence interval (CI) of the results.
In addition to bootstrapping, Cox regression models were used to evaluate the effect of RT after adjusting for other prognostic factors identified in prior work (10) , and to evaluate the statistical significance of the interaction between the effect of RT on EFS and the clinical factors identified in the RPA.
Results

Patients
Patient characteristics are shown in Table 1 . Among the 716 RER/CR patients, 355 patients received IFRT, whereas 361 patients had no further immediate treatment after their chemotherapy. The median age of the cohort was 14 years (range, 2-21 years). There was a slight predominance of male patients (56.1%). Most of the patients (nZ464, 64.8%) had clinical stage I/II disease, with only a minority of patients presenting with stage IV (nZ85, 11.9%). Bulky disease was present in 494 patients (69%), including 199 patients with LMA. Median follow-up was 4.1 years (range, 0.3-8.6 years).
Treatment results
Differences in 4-year EFS associated with IFRT among patients with different clinical factors are shown in Table 2 . In univariate analysis, anemia was the only single clinical variable associated with a statistically significant improvement in EFS at 4 years after randomization to IFRT 
Predictive analysis of combined clinical factors
The RPA identified 17 combinations of clinical variables in which the 4-year EFS was >7% better after randomization to IFRT, with at least 10 events in each treatment arm (Table 3) . The combination of anemia and stage I/II disease predicted significantly better EFS after randomization to IFRT after chemotherapy among RER/CR patients (4-year EFS of 90.2% vs 79.5% among those receiving chemotherapy alone; HR 2.34, 95% CI 1.16-4.72, PZ.015; Fig. 1 ). In bootstrap analyses, for patients with anemia and stage I/II disease the median increase in 4-year EFS associated with IFRT was 10.5% (95% CI 1.2%-19.7%), and the median HR associated with the omission of RT was 2.37 (95% CI 1.17-5.13). After adjusting for albumin level and the presence of B symptoms, the event rate remained significantly higher without the use of IFRT among anemic stage I/II patients (HR 2.51, 95% CI 1.24-5.08; Appendix E1; available online at www.redjournal. org). Further, in a 3-variable Cox model including treatment (combined modality vs chemotherapy alone), clinical factors (anemia þ Stage I/II vs other), and an interaction term, the interaction was statistically significant (PZ.045), suggesting that RT had a significantly greater effect on EFS in this group of patients than other patients achieving RER/CR.
Importantly, the intermediate-risk eligibility required all patients with stage I/II disease in this study to have at least one of bulk disease, B symptoms, or extranodal involvement. Among these criteria, the presence of bulky limited-stage disease in combination with anemia (nZ190) was associated with a significantly lower EFS after randomization to chemotherapy alone: 4-year EFS 77.9% versus 89.3% with combined modality; (HR 2.38, 95% CI 1.13-4.99; Figure 2 and Table 3 ). After adjustment for other risk factors, the effect of IFRT on EFS remained significant (HR 2.59, 95% CI 1.23-5.45). Further breakdown of this group was limited by statistical power, although the discrepancy in EFS between randomized arms was most pronounced among those with anemia and limited-stage LMA, where the 4-year EFS was only 66.1% among patients randomized to chemotherapy alone, compared with 85.5% among those randomized to combined modality therapy (HR 2.67, 95% CI 1.02-6.94; Appendix E1; available online at www.redjournal.org).
FDG-PET Analysis
Among the RER/CR patients with anemia and bulky limited-stage disease, 135 had an FDG-PET evaluation of response after 2 cycles of chemotherapy, and 101 had a negative result on PET. For this subgroup of patients with a rapid response on both PET and CT, randomization to IFRT was associated with a 6.5% superior 4-year EFS (91.5% vs 85.0%), which was not statistically significant (PZ.29). For the small number of patients (nZ34) with anemia, bulky stage I/II disease and a positive or equivocal PET scan after 2 cycles of chemotherapy, the 4-year EFS was 76.5% among those randomized to IFRT and 68.9% for those treated with chemotherapy alone (PZ.36; Appendix E1; available online at www.redjournal.org).
Discussion
Few randomized trials exist to indicate which children with HL can be treated without RT without reduction in their EFS. The Children's Cancer Group 5942 study found that patients in CR (according to CT imaging) after chemotherapy randomly assigned to IFRT had a significantly superior 10-year EFS compared with those treated with chemotherapy alone (91.2% vs 82.9%, PZ.004) (7). In the nonrandomized German Society of Pediatric Oncology and Hematology Hodgkin's Disease 2002 study, IFRT was Abbreviations: EFS Z event-free survival; HR Z hazard ratio. * Differences in EFS >0 indicate superiority of combined modality therapy over chemotherapy alone among patients with RER/CR.
y Values >1 indicate superiority of combined modality therapy.
omitted for early-stage patients with a CR to initial chemotherapy, without an apparent decrement in EFS (91.7% vs 93.2% with and without IFRT, respectively) (1). However, the criteria for CR on this trial were very strict, and 67.0% of early-stage patients were treated with combined modality therapy. Early chemotherapy response is an important predictor of EFS in pediatric HL, and response evaluation after 2 cycles of chemotherapy may be a more accurate means of identifying patients who will be cured without RT (11, 12) . The COG AHOD 0031 trial demonstrated that among intermediate-risk RER/CR patients, IFRT could be omitted after 4 cycles of ABVE-PC with no significant reduction in 4-year EFS (2) .
However, our results suggest that using imaging response alone to select patients for IFRT may oversimplify the clinical heterogeneity among patients achieving RER/CR and conceal important variation in the effect of IFRT among those with a rapid response to chemotherapy. Moreover, the use of any single clinical factor to select patients for IFRT also seems to be suboptimal. For example, although peripheral bulk and bulky mediastinal involvement are risk factors for inferior EFS (3) and have traditionally been considered indications for RT, our findings suggest that when considered in isolation, neither were clear indications that RT significantly improved outcome. Instead, a constellation of clinical featuresdanemia with bulky limited stagedbetter identified patients who had significant clinical benefit from combined modality therapy, suggesting that although the majority of RER/CR patients may not benefit from IFRT, these clinical factors can be used to aid identification of the minority who do.
Hodgkin lymphomaeassociated anemia and bulk disease have been associated with poor prognosis in other studies (13, 14) , and it is possible that any form of treatment intensification, including additional chemotherapy, could have overcome the inferior outcome seen in this Abbreviations: CI Z confidence interval; EFS Z event-free survival; HR Z hazard ratio; LMA Z large mediastinal adenopathy. * Difference in EFS observed in the primary trial results for the specified clinical group (values >0 favor combined modality therapy). Trial eligibility required patients with stage I-II disease to have one of bulk disease, B symptoms, or extranodal involvement.
y HR for EFS observed in the primary trial results (HR >1 favors combined modality therapy). z Median difference in 4-year EFS among 1000 bootstrap iterations comparing combined modality therapy observation in the specified clinical group (and 95% CI of bootstrap estimates).
x Median HR of EFS among 1000 bootstrap iterations comparing combined modality therapy versus chemotherapy alone in the specified clinical group, and 95% CI of bootstrap estimates.
Volume 96 Number 5 2016 group. The benefit of RT as consolidation in these patients is likely explained at least in part by the fact that IFRT delivered in this protocol encompassed all sites of disease, whereas for stage IV patients it would not. It is also notable that HL patients with anemia have been found to have elevated levels of hepcidin, a liver-produced peptide that inhibits iron release from macrophages, the liver, and the reticuloendothelial system (15) . Intracellular iron can act as a radiosensitizer (16, 17) , and our findings are consistent with the possibility that intracellular iron accumulation in the tumor-associated macrophages could have a radiationsensitizing effect in HL patients. The recent UK-RAPID and EORTC/LYSA/FIL H10 adult trials have tested PET-based, response-adapted strategies as a means of avoiding IFRT among patients with early-stage favorable (18, 19) or unfavorable (19) disease. These studies demonstrated that despite very good EFS among favorable-risk patients who were PETnegative after 2 or 3 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), omission of IFRT based on early PET response was still associated with a decrement in EFS, although whether the magnitude of this decrement is clinically significant remains controversial. Our PET-related findings are consistent with the finding of the overall study results (2), insofar as the impact of IFRT among RER/CR patients was not significantly different among those with positive or negative PET results. The sample size, however, precludes meaningful conclusions. Overall, although the adoption of interim PET imaging seems to provide prognostic information, it has not solved the challenge of selecting optimal treatment intensity.
Strengths of this study include the randomized trial structure and the use of RPA to evaluate factors predictive of clinically significant improvement in EFS with adjuvant IFRT. Identification of patients who do or do not benefit from RT is a major focus of clinical concern, and our predictive factor analysis addresses this concern directly. This is in contrast to prognostic factor evaluation, which is more suitable for creating clinical risk groups that can guide the overall intensity of treatment, but does not necessarily identify which patients benefit from specific treatments. Further, the use of RPA facilitates the modeling of complex interactions while avoiding assumptions regarding the linear relationship among variables. Finally, the use of bootstrapping to evaluate the robustness of the results limits the possibility that our findings will not be reproducible in other settings because of overfitting of the data.
However, this analysis also has limitations that warrant consideration. For several subsets of patients, the sample size was small, with limited statistical power to evaluate differences in relapse risk that could be considered clinically significant. This highlights the challenge of studying a relatively uncommon cancer for which the relapse rate is low. Further, despite efforts to limit the effect of overfitting the data, all patients were treated with the same chemotherapy regimen, and the use of a different regimen could potentially produce different findings. Finally, we note that labeling a 7% improvement in EFS as "clinically significant" represents a largely value-laden threshold. In practice, this threshold will differ among individual patients, and we strongly advocate that patients' individual preferences be the source of establishing what treatment effects are clinically important.
